Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Debrisoquine 4-hydroxylation and the Balkan endemic nephropathy.

Mantle PG, Amirtharajah M, Klippel S, Miljkovic A, Naik JT, Nestler S.

Nephron. 1999;81(3):347-8. No abstract available.

PMID:
10050092
3.

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.

Llerena A, Dorado P, Peñas-Lledó EM.

Pharmacogenomics. 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. Review.

PMID:
19102711
4.

[Debrisoquine hydroxylation test as an example of new possibilities of research in psychopharmacology].

Jarema M.

Psychiatr Pol. 1995 Jan-Feb;29(1):57-66. Review. Polish.

PMID:
7878155
5.

Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype.

Llerena A, Cobaleda J, Martínez C, Benítez J.

Eur J Drug Metab Pharmacokinet. 1996 Apr-Jun;21(2):129-38. Review.

PMID:
8839686
6.

Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation.

Bertilsson L, Dahl ML, Ekqvist B, Llerena A.

Psychopharmacol Ser. 1993;10:230-7. Review. No abstract available.

PMID:
8103225
7.

Environmental renal disease: lead, cadmium and Balkan endemic nephropathy.

Wedeen RP.

Kidney Int Suppl. 1991 Nov;34:S4-8. Review.

PMID:
1762331

Supplemental Content

Support Center